Unjoni Ewropea - Iżlandiż - EMA (European Medicines Agency)

midas pharma gmbh - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - augnlækningar - ranivisio is indicated in adults for:• the treatment of neovascular (wet) age-related macular degeneration (amd)• the treatment of visual impairment due to diabetic macular oedema (dme)• the treatment of proliferative diabetic retinopathy (pdr)• the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)• the treatment of visual impairment due to choroidal neovascularisation (cnv).

Unjoni Ewropea - Iżlandiż - EMA (European Medicines Agency)

pari pharma gmbh - tóbramýcíni - respiratory tract infections; cystic fibrosis - sýklalyf fyrir almenn nota, - vantobra er ætlað fyrir stjórnun langvarandi lungum sýkingu vegna pseudomonas tilhneiging til að hætta í sjúklinga á aldrinum 6 ára og eldri fengið lungnasjúkdóm (samanber). Íhuga ætti að opinbera leiðsögn á réttri notkun af sýklalyfjum.

Unjoni Ewropea - Iżlandiż - EMA (European Medicines Agency)

plusultra pharma gmbh - sirolimus - angiofibroma; tuberous sclerosis - hyftor is indicated for the treatment of facial angiofibroma associated with tuberous sclerosis complex in adults and paediatric patients aged 6 years and older.

Unjoni Ewropea - Iżlandiż - EMA (European Medicines Agency)

juta pharma gmbh - pegfilgrastim - daufkyrningafæð - Ónæmisörvandi, - lækkun á lengd mæði í tengslum og tíðni hita og mæði í tengslum í fullorðinn sjúklinga með frumudrepandi lyfjameðferð fyrir illkynja (með undantekning langvarandi merg hvítblæði og myelodysplastic heilkennum).

Unjoni Ewropea - Iżlandiż - EMA (European Medicines Agency)

esteve pharmaceuticals gmbh - thiotepa - hematopoietic stem cell transplantation; neoplasms - Æxlishemjandi lyf - thiotepa riemser is indicated, in combination with other chemotherapy medicinal products:with or without total body irradiation (tbi), as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (hpct) in haematological diseases in adult and paediatric patients;when high dose chemotherapy with hpct support is appropriate for the treatment of solid tumours in adult and paediatric patients. thiotepa riemser is indicated, in combination with other chemotherapy medicinal products:with or without total body irradiation (tbi), as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (hpct) in haematological diseases in adult and paediatric patients;when high dose chemotherapy with hpct support is appropriate for the treatment of solid tumours in adult and paediatric patients.

Unjoni Ewropea - Iżlandiż - EMA (European Medicines Agency)

aop orphan pharmaceuticals gmbh - sugammadex sodium - taugakerfi - Öll önnur lækningavörur - afturköllun taugavöðvablokkunar sem valdið er af rócuronium eða vecuronium. for the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.

Islanda - Iżlandiż - LYFJASTOFNUN (Icelandic Medicines Agency)

hameln pharma gmbh - remifentanilum hýdróklóríð - stofn fyrir stungulyfs-/innrennslisþykkni, lausn - 2 mg

Islanda - Iżlandiż - LYFJASTOFNUN (Icelandic Medicines Agency)

g.l. pharma gmbh - tramadolum hýdróklóríð - filmuhúðuð tafla - 50 mg

Unjoni Ewropea - Iżlandiż - EMA (European Medicines Agency)

tad pharma gmbh - clopidogrel (as hydrochloride) - peripheral vascular diseases; stroke; myocardial infarction - blóðþurrðandi lyf - clopidogrel is indicated in adults for the prevention of atherothrombotic events in: , patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease.

Islanda - Iżlandiż - LYFJASTOFNUN (Icelandic Medicines Agency)

hameln pharma gmbh - sugammadex sodium - stungulyf, lausn - 100 mg/ml